Abstract
Introduction: it was to investigate the relationship between pre-delivery serumβ-human chorionic gonadotropin (β-HCG), fibrinogen (FIB), and homocysteine (HCY) with hypertensive disorder complicating pregnancy (HDCP). Materials and Methods: 200 HDCP patients and 150 normal pregnant women were selected as study subjects. Fasting cubital venous blood samples were collected to measure serum triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), as well as β-HCG, FIB, and HCY levels. Pearson correlation analysis examined relationship between β-HCG, FIB, HCY, and HDCP. Receiver operating characteristic (ROC) curve analysis evaluated the predictive value of these indicators for HDCP. Multiple logistic regression analysis identified risk factors (RFs) for HDCP.Results: serum TG, TC, HDL, LDL, FIB,β-HCG, and HCY were greatly elevated in the HDCP group versus control group (CG) (P<0.05). Serumβ-HCG, FIB, and HCY showed notable positive correlations with HDCP (r = 0.935, 0.547, 0.811; P<0.05), and the areas under the ROC curve (AUC) for predicting HDCP based on serum β-HCG, FIB, HCY, and their combination were 0.743, 0.659, 0.801, and 0.886, respectively (P<0.05). Lipid indicators and serum levels of FIB, β-HCG, and HCY were RFs for HDCP.Conclusion:pregnant women with HDCP exhibited markedly elevated serum lipid levels and FIB, β-HCG, and HCY levels before delivery, which can serve as predictive indicators for HDCP.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.